Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to include SNAP-CAR NK cells, has potential to impact various autoimmune diseases in addition to oncology indications.
Save time and jump to the most important pieces.
Gainers Mustang Bio (NASDAQ:MBIO) stock increased by 51.6% to $0.47 during Wednesday's pre-market session. The market value of their outstanding shares is at $5.8 million. NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 30.78% to $5.99. The market value of their outstanding shares is at $29.3 million. Rezolute (NASDAQ:RZLT) shares rose 25.0% to $3.75. The company's market cap stands at $150.5 million. Akso Health Group (NASDAQ:AHG) stock moved upwards by 16.26% to $1.0. The market value of their outstanding shares is at $146.6 million. Coeptis Therapeutics (NASDAQ:COEP) shares increased by 15.72% to $0.39. The company's market cap stands at $14.4 million. Qilian Intl Hldg Gr
Gainers Orgenesis (NASDAQ:ORGS) shares increased by 8.5% to $0.63 during Thursday's after-market session. The company's market cap stands at $21.4 million. AN2 Therapeutics (NASDAQ:ANTX) shares increased by 6.76% to $3.47. The company's market cap stands at $103.3 million. GRI Bio (NASDAQ:GRI) stock increased by 6.65% to $0.54. NuCana (NASDAQ:NCNA) shares rose 5.92% to $0.25. The market value of their outstanding shares is at $13.4 million. Stoke Therapeutics (NASDAQ:STOK) shares increased by 5.42% to $12.83. The company's market cap stands at $594.0 million. Candel Therapeutics (NASDAQ:CADL) stock moved upwards by 4.99% to $6.72. The market value of their outstanding shares is at $197
Study results demonstrate the safety and feasibility of adoptive immunotherapy using allogeneic off-the-shelf NK cells in hospitalized patients with COVID at high risk for progression of disease DVX201, the first allogeneic NK cell therapy derived from pooled donor cord blood CD34+ cells, was administered to 9 patients with no dose limiting toxicities, cytokine release syndrome or infusion toxicities WEXFORD, Pa., Nov. 7, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced that results from their Phase 1 st
WEXFORD, Pa., Oct. 24, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced the expansion of its license agreement with Deverra Therapeutics Inc. ("Deverra"), broadening the potential applications of its allogeneic natural killer (NK) cell technology. This expansion includes the use of unmodified NK cells in treating viral infections, pandemic-related illnesses, and emergency stockpiling for future health crises.
WEXFORD, Pa., Oct. 15, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, announced that its Chief Scientific and Medical Officer Colleen Delaney, MD will attend and present at the following upcoming fall conferences. These events, including the 2024 AABB Annual Meeting, the 50th ASHI Annual Meeting, the Advanced Therapies USA Congress, and the Donor Selection & Cell Source Summit, offer an opportunity to expand awareness of Coeptis' advancements in universal cell therapy and its potential to transform patient outcomes.
Dr. Delaney joins Coeptis after securing exclusive rights from Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs WEXFORD, Pa., Aug. 30, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that Colleen Delaney, MD, MSc, has been appointed Chief Scientific and Medical Officer of Coeptis following the completion of an exclusive rights agreement with Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs.
15-year accounting and finance career spans several sectors including life sciences and underscores financial leadership abilities WEXFORD, Pa., May 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced today the appointment of Brian Cogley, MBA, to the position of Chief Financial Officer (CFO) effective immediately. Mr. Cogley brings 15 years of accounting and finance experience to Coeptis, having previously held positions of increasing authority at two "Big 4" accounting firms and served on the management teams of multiple companies in diverse in
Coeptis bolsters pipeline with two Phase 1 clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML)/high risk MDS and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors WEXFORD, Pa., Aug. 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that it has completed the exclusive license of key assets from Deverra Therapeutics Inc. ("Deverra") related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generat
SC 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)
DEF 14A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
10-Q - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
8-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)